Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2011

View Archived Issues

GABA-AT inhibitor shows promise to treat epilepsy and drug addiction

Tianjin Institute of Pharmaceutical Research discloses new agents for diabetes

Johnson & Johnson presents potential novel approach to treat diabetes and obesity

New gamma-secretase modulator shows promise in Alzheimer's disease models

Promising phase II data on NH-004 trigger additional grant from MJFF to NeuroHealing Pharmaceuticals

Apremilast completes phase II study in vulvar pain

New cannabinoid CB2 receptor agonists described

Bristol-Myers Squibb presents new chemokine CCR2 receptor modulators

Biotica claims novel sanglifehrin analogues for viral infections

British company patents novel neuropeptide Y2 receptor ligands

New monoamine reuptake inhibitors synthesized at NeuroSearch

Cleveland-based researchers to jointly launch phase I stem cell trial for MS

KemPharm and MonoSol Rx to codevelop KP-415 for ADHD

Enrollment complete in three phase III studies of TMC-435

Kuros Biosurgery completes enrollment in diabetic foot ulcer study

MorphoSys initiates dosing in MOR-202 multiple myeloma trial

DSMB recommends continuation of pivotal X-PECT study of perifosine

Tarceva approved in E.U. for specific subtype of non-small cell lung cancer

Anacor and MMV extend development agreement for malaria drug

Mitsubishi Tanabe files for approval of tenegliptin in Japan

Titan Pharmaceuticals schedules pre-NDA meeting for Probuphine

Bristol-Myers and Health Canada issue new safety information regarding Sprycel

Kissei obtains Japanese rights to DNA topoisomerase 2 inhibitor for anthracycline extravasation

Data presented from metastatic colorectal cohort of phase II trial of Delcath chemosaturation system

New approval for Cipher Pharmaceuticals' CIP-Tramadol ER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...